ArticleThe American journal of pathology2011
Functional contributions of N- and O-glycans to L-selectin ligands in murine and human lymphoid organs.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Expression of Heart Development Protein With EGF-Like Domains 1 (HEG1) Decorated With Low-Sulfated Keratan Sulfate in Human Malignant Pleural Mesothelioma.Pathology international · 2025Article
- GlcNAc6ST2/CHST4 Is Essential for the Synthesis of R-10G-Reactive Keratan Sulfate/SulfatedMolecules (Basel, Switzerland) · 2024Article
- The role of galectins in mediating the adhesion of circulating cells to vascular endothelium.Frontiers in immunology · 2024Review
- Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- A novel monoclonal antibody against 6-sulfo sialyl Lewis x glycans attenuates murine allergic rhinitis by suppressing Th2 immune responses.Scientific reports · 2023Article
- High endothelial venules as potential gateways for therapeutics.Trends in immunology · 2022Review
- Complementary Role of GlcNAc6ST2 and GlcNAc6ST3 in Synthesis of CL40-Reactive Sialylated and Sulfated Glycans in the Mouse Pleural Mesothelium.Molecules (Basel, Switzerland) · 2022Article
- High endothelial venules (HEVs) in immunity, inflammation and cancer.Angiogenesis · 2021Review
- Stepwise transmigration of T- and B cells through a perivascular channel in high endothelial venules.Life science alliance · 2021Article
- Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.Cellular and molecular life sciences : CMLS · 2021Review
- Material design for lymph node drug delivery.Nature reviews. Materials · 2019Article
- Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO.Frontiers in immunology · 2016Review
- Novel Antibodies Reactive with Sialyl Lewis X in Both Humans and Mice Define Its Critical Role in Leukocyte Trafficking and Contact Hypersensitivity Responses.The Journal of biological chemistry · 2015Article
- Understanding high endothelial venules: Lessons for cancer immunology.Oncoimmunology · 2015Review
- Tools to MSn Sequence and Document the Structures of Glycan Epitopes.Discovering the subtleties of sugars : proceedings of the 3rd Beilstein Glyco-Bioinformatics Symposium : June 10th - 14th, 2013, Potsdam, Germany. International Beilstein Symposium on Glyco-Bioinformatics (3rd : 2013 : Potsdam, Germany) · 2014Article
- Remodeling of marrow hematopoietic stem and progenitor cells by non-self ST6Gal-1 sialyltransferase.The Journal of biological chemistry · 2014Article
- Preferential binding of an odor within olfactory receptors: a precursor to receptor activation.Chemical senses · 2014Article
- KSGal6ST generates galactose-6-O-sulfate in high endothelial venules but does not contribute to L-selectin-dependent lymphocyte homing.Glycobiology · 2013Article
- HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes.Nature reviews. Immunology · 2012Review
- Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases.Seminars in immunopathology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
L-selectin initiates lymphocyte interactions with high endothelial venules (HEVs) of lymphoid organs through binding to ligands with specific glycosylation modifications. 6-Sulfo sLe(x), a sulfated carbohydrate determinant for L-selectin, is carried on core 2 and extended core 1 O-glycans of HEV-expressed glycoproteins. The MECA-79 monoclonal antibody recognizes sulfated extended core 1 O-glycans and partially blocks lymphocyte-HEV interactions in lymphoid organs. Recent evidence has identified the contribution of 6-sulfo sLe(x) carried on N-glycans to lymphocyte homing in mice. Here, we characterize CL40, a novel IgG monoclonal antibody. CL40 equaled or surpassed MECA-79 as a histochemical staining reagent for HEVs and HEV-like vessels in mouse and human. Using synthetic carbohydrates, we found that CL40 bound to 6-sulfo sLe(x) structures, on both core 2 and extended core 1 structures, with an absolute dependency on 6-O-sulfation. Using transfected CHO cells and gene-targeted mice, we observed that CL40 bound its epitope on both N-glycans and O-glycans. Consistent with its broader glycan-binding, CL40 was superior to MECA-79 in blocking lymphocyte-HEV interactions in both wild-type mice and mice deficient in forming O-glycans. This superiority was more marked in human, as CL40 completely blocked lymphocyte binding to tonsillar HEVs, whereas MECA-79 inhibited only 60%. These findings extend the evidence for the importance of N-glycans in lymphocyte homing in mouse and indicate that this dependency also applies to human lymphoid organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.